A randomized controlled study of iron supplementation in patients treated with erythropoietin

Kidney International

Volumn 50, Issue 5, 1996, Pages 1694-1699

  Macdougall, Iain C ^a,b   Tucker, Beatriz ^a   Thompson, Joanne ^a   Tomson, Charles R V ^a   Baker, Laurence R I ^a   Raine, Anthony E G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS SULFATE; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON THERAPY; KIDNEY DISEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029952883     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.487     Document Type: Article

References (29)

1. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987
2. MACDOUGALL IC, HUTTON RD, CAVILL I, COLES GA, WILLIAMS JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299:157-158, 1989
3. VAN WYCK DB, STIVELMAN JC, RUIZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 35:712-716, 1989
4. ESCHBACH JW, DOWNING MR, EGRIE JC, BROWNE JK, ADAMSON JW: USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76:160-165, 1989
5. SCHAEFER RM, SCHAEFER L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3:71-75, 1992
6. MACDOUGALL IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opinion Nephrol Hypertens 3:620-625, 1994
7. ANASTASSIADES EG, HOWARTH D, HOWARTH J, SHANKS D, WATERS HM, HYDE K, GEARY CG, YIN JAL, GOKAL R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
8. LEVIN NW, LAZARUS JM, NISSENSON AR: National Cooperative rHu Erythropoietin Study in patients with chronic renal failure: An interim report. Am J Kidney Dis 22(Suppl 1):3-12, 1993
9. SUNDER-PLASSMANN G, HÖRL WH: Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 72:S11-S15, 1994
10. HUSSEIN S, PRIETO J, O'SHEA M, HOFFBRAND AV, BAILLOD RA, MOORHEAD JF: Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J 1:546-548, 1975
11. WORWOOD M: Serum ferritin, in Methods in Haematology, Vol 1: Iron, edited by COOK JD, New York, Churchill Livingstone, 1980, pp 58-89
12. ROSENBERG ME: Role of transferrin measurement in monitoring iron status during recombinant human erythropoietin therapy. Dial Transplant 21:81-90, 1992
13. BAINTON DF, FINCH CA: The diagnosis of iron deficiency anemia. Am J Med 37:62-70, 1964
14. CAVILL I: Diagnostic methods. Clinics in Haematol 11:259-273, 1982
15. MACDOUGALL IC, CAVILL I, HULME B, BAIN B, MCGREGOR E, MCKAY P, SANDERS E, COLES GA, WILLIAMS JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 304:225-226, 1992
16. SCHAEFER RM, SCHAEFER L, HEIDLAND A: The hypochromic red cell: A new parameter for the monitoring of iron therapy during rhEPO treatment. Clin Invest 72:B10, 1994
17. HÖRL WH, DREYLING K, STEINHAUER HB, ENGELHARDT R, SCHOLLMEYER P: Iron status of dialysis patients under rHuEPO therapy. Contrib Nephrol 87:78-86, 1990
18. PIAZZA V, VILLA G, GALL F, SEGAGNI S, BOVIO G, POGGIO F, PACARDI L, SALVEDEO A: Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis. Nephron 61:54-57, 1992
19. FISHBANE S, LYNN RI: The utility of zinc protoporphyrin as an assay for iron deficiency in hemodialysis patients. (abstract) J Am Soc Nephrol 4:425, 1993
20. KANAKAKORN K, CAVILL I, JACOBS A: The metabolism of intravenously administered iron-dextran. Br J Haem 25:637-643, 1973
21. CAVILL I, MACDOUGALL IC: Erythropoiesis and iron supply in patients treated with erythropoietin. Erythropoiesis 3:50-55, 1992
22. ESCHBACH JW, COOK JD, FINCH CA: Iron absorption in chronic renal disease. Clin Sci 38:191-196, 1970
23. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE, LEDINGHAM JGG, OLIVER DO: Iron metabolism in haemodialysis patients. Q J Med 48:369-391, 1979
24. SKIKNE BS, COOK JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 120:746-751, 1992
25. DONNELLY SM, POSEN GA, ALI MAM: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991
26. GLASGOW L, AL-HAIDARY A, KIRLIN L, SCHIFMAN R, VAN WYCK DB: Low dose iron challenge test to compare bioavailability of oral iron agents. Natnl Kid Found Abstract Book 1993
27. BIRGEGARD G: Erythropoiesis and inflammation. Contrib Nephrol 76:330-341, 1989
28. HAMSTRA RD, BLOCK MH, SCHOCKET AL: Intravenous iron dextran in clinical medicine. JAMA 243:1726-1731, 1980
29. GEISSER P, BAER M, SCHAUB E: Structure/histotoxicity relationship of parenteral iron preparations. Arzneim Forsch 42:1439-1452, 1992